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Introduction
Accessory spleen is a normal anatomic variant that oc-
curs in approximately 10% of  the population. Several re-
ports describe an intrapancreatic accessory spleen that was 
misdiagnosed as a nonsecreting endocrine tumor, since it 
exhibits positive somatostatin receptors (SSTRs). The ac-
cessory spleen poses a diagnostic challenge even in its ex-
trapancreatic location, mimicking a lymph node metastasis 
or a local recurrence of  a pancreatic neuroendocrine tu-
mor. An accurate diagnosis is crucial, since such an acces-
sory spleen does not require surgical treatment. 
During the fifth week of  gestation, the spleen develops in 
the dorsal mesogastrium from mesenchymal cells that mi-
grate between the leaves of  the mesentery and coalesce. An 
accessory spleen may arise from isolated cells that stay 
separated from the main body of  the spleen. In a large se-
ries of  nonselected autopsy investigations, an accessory 
spleen was found in 10–30%. (1, 2, 3). In 1,000 consecutive 
patients undergoing contrast-enhanced abdominal CT 
scan, an accessory spleen was present in 16% (1, 4). In 
80%, the accessory spleen is located at or near the splenic 
hilum. The second most common site is the pancreatic tail 
(17%) (1, 3).
Case report
A 59-year-old woman underwent pancreatectomy and 
splenectomy as consequence of  well-differentiated neuro-
endocrine tumor (NET) (pT3, N1, M0). Four years later, 
she was referred to our department for followup 
DOTATOC-scintigraphy after a slight elevation of  chro-
mogranin A. Other laboratory tests revealed normal CA 
19-9 and carcinoembryonic antigen. However, somatostatin 
receptor scintigraphy using 68Ga DOTATOC-PET/CT 
showed a positive uptake in a round mass in the upper left 
abdominal region (Fig. 1).
This finding could have been a sign of  recurrence of  
NET, considering the elevation of  chromogranin A. How-
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ever, due to its location and round shape, we felt that an 
accessory spleen should be strongly considered in the dif-
ferential diagnosis, especially after splenectomy. 
The critical test that enabled us to determine the lesion's 
origin turned out to be SS. It demonstrated the ability of  
the described round mass to accumulate 99mTc-tagged 
heat-damaged red blood cells, which is a characteristic of  
splenic tissue (Fig. 2).
It is also worth mentioning that a 99mTc sulfur colloid 
scan with single-photon-emission computed tomography 
(SPECT) could accomplish the same goal as 99mTc heat-
denatured red cells for this purpose.
Consequently, the recurrent NET was excluded in favor 
of  an accessory spleen exhibiting positive SSTRs. This case 
shows the benefit of  using SS as the method of  choice in 
distinguishing SSTR-positive accessory spleen from recur-
rent NET.
Discussion
   Somatostatin receptor scintigraphy (SRS) detects neu-
roendocrine gastroenteropancreatic (GEP) tumors with a 
high sensitivity (70% to 95%). It may detect primary and 
metastatic endocrine tumors not visualized by other imag-
ing techniques, therebt affecting patient management (5).
Somatostatin is a small regulatory peptide that functions 
as a neurotransmitter and has inhibitory and antiprolifera-
tive effects. It binds to somatostatin receptors and has sev-
eral identified subclasses: SSTR1, 2a, 2b, 3, 4, and 5.7. The 
commercially available somatostatin analog, pentetreotide, 
is labeled with 111Indium.
68Gallium somatostatin analogs, DOTATOC (DOTA0, 
D -Phe1, Tyr(3)-octreotate DOTATATE, and DOTA 1-
Nal3-octreotide (DOTANOC) are widely used for PET 
imaging with promising results, but are not currently ap-
proved for clinical use in the USA (6). However, SRS may 
also lead to false-positive results; this is due to the presence 
of  SSTRs on the surface of  lymphocytes within the splenic 
tissue, which also attach SSTR ligands with a high affinity 
and produce images similar to a recurrent endocrine tumor 
(5).
In Prasad and Baum’s study (7), the highest uptake of  
68Ga-DOTANOC was found in the spleen. Considering 
this result and many others, the spleen tissue (spleen and 
accessory spleen) can definitely be visualized with SRS. 
Several reports describe an intrapancreatic accessory spleen 
that was misdiagnosed as a nonsecreting endocrine tumor 
(8. 9); our report describes a possible misdiagnosis in case of 
extrapancreatic accessory spleen. 
Since the accessory spleen exhibits positive SSTR, it 
poses a diagnostic challenge even in its extrapancretic loca-
tion, mimicking a lymph node metastasis or local recur-
rence of  a pancreatic NET. However, definitive diagnosis 
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Figure 1. 59-year-old woman with accessory spleen. 
DOTATOC-PET/CT after intravenous injection of 206 MBq 
68Ga DOTATOC; the axial and coronal planes show an in-
creased focal uptake that corresponds with a nodular lesion 
(diameter, 15 mm) in the left upper abdominal region 
(arrows). 
Figure 2. 59-year-old woman with accessory spleen. 
Splenic scintigraphy using 99mTc-tagged heat-damaged 
red-blood-cell scintigraphy, Scintigraphic image (left) and 
SPECT/CT fused image (right) demonstrate an uptake in 
the round nodule (arrows) that already exhibited a signifi-
cant uptake of 68Ga-DOTATOC, confirming the diagnosis of 
accessory spleen.
based on conversional imaging modalities can be difficult 
because CT scan, MRI, and ultrasound images of  such 
accessory spleens can be quite similar to those of  recurrent 
tumor (Fig. 3). The optimal method is to identify the splenic 
tissue using  99mTc-tagged heat-damaged red-blood-cell 
scintigraphy, thus providing a simple, sensitive, and specific 
method for recognizing the accessory spleen.
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Figure 3. 59-year-old woman with accessory spleen. Oblique position modified 
contrast-enhanced abdominal CT. Modified oblique axial plane (left) and oblique co-
ronal plane (right) show the confirmed accessory spleen, whose diameter is 15 mm 
(arrows).
